At what enterprise value was EXSCIENTIA acquired in 2024?

You can find the full valuation details of EXSCIENTIA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of EXSCIENTIA when it was acquired by RECURSION PHARMACEUTICALS?

The exact EV/EBITDA multiple for EXSCIENTIA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was EXSCIENTIA acquired by RECURSION PHARMACEUTICALS?

EXSCIENTIA was acquired by RECURSION PHARMACEUTICALS in 2024.

What was the revenue of EXSCIENTIA at the time of the deal?

The revenue of EXSCIENTIA at the time of the deal is estimated to be in the range of 10M - 30M GBP. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of EXSCIENTIA during the acquisition?

EXSCIENTIA's EBITDA is estimated to be in the range of 0M - 5M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the EXSCIENTIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the EXSCIENTIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.zonebourse.com/cours/action/RECURSION-PHARMACEUTICALS-121456074/actualite/L-entreprise-de-biotechnologie-Recursion-rachete-Exscientia-pour-688-millions-de-dollars-47597416/

← DATABASE

Home Database Healthcare & PharmaEXSCIENTIA

08/2024

EXSCIENTIA acquired by RECURSION PHARMACEUTICALS

UNITED KINGDOM Life Sciences / Pharma & Biotech / R&D Biotech REV 10M - 30M GBP

Context

Recursion Pharmaceuticals has entered into a definitive agreement to acquire Exscientia in an all-stock transaction. This strategic move aims to bring together two artificial intelligence-driven drug discovery specialists, creating a comprehensive platform that spans the entire process, from biology to computational chemistry. The deal is structured as a stock swap, where Recursion shareholders will hold the majority of the combined entity's capital, while Exscientia shareholders will receive a minority stake in the new company. The strategic rationale behind this merger is to combine complementary technological approaches, with Recursion focusing on large-scale biological analysis and Exscientia bringing advanced AI-driven molecular design expertise. The combined company will retain the Recursion name and benefit from a strengthened financial foundation, including significant cash reserves to support its operations for several years. The transaction is also expected to generate substantial synergies by leveraging shared technological platforms, data, and research capabilities, with the ambition of accelerating the discovery of new drug candidates and enhancing the overall efficiency of pharmaceutical development programs.

EXSCIENTIA, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Exscientia is a UK-based biotechnology company that specializes in AI-driven drug discovery. The company develops technological platforms that leverage algorithmic approaches to identify, design, and optimize novel therapeutic molecules, combining machine learning, predictive modeling, and medicinal chemistry expertise. By doing so, Exscientia aims to accelerate the initial stages of pharmaceutical research, which are traditionally time-consuming and costly, by enhancing the selection of promising drug candidates and reducing failure rates in development. The company focuses on key therapeutic areas such as oncology and immunology, collaborating with international pharmaceutical partners. It also has a pipeline of clinical-stage drug candidates emerging from its proprietary molecular design platform. As a pioneer in applying AI to drug discovery, Exscientia combines advanced computational capabilities with scientific expertise to optimize the identification of new therapeutic targets, streamlining the drug development process and improving patient outcomes.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Life Sciences	Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO
09/2024	AGILENT TECHNOLOGIES	BIOVECTRA	CANADA	Life Sciences	Agilent Technologies has finalized the acquisition of BIOVECTRA, a move designed to fundamentally expand the group's contract development and manufacturing (CDMO) portfolio into fast-growing therapeutic modalities
08/2024	NORDSON CORPORATION	ATRION CORPORATION	UNITED STATES	Life Sciences	Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical
07/2024	ROCHE	LUMIRADX	UNITED KINGDOM	Life Sciences	The acquisition of the point-of-care technology platform from the LumiraDx group marks a transformative technical reinforcement of the acquirer's diagnostic ecosystem. The strategic rationale for this transaction centers on a "decentralization" play, merging the target's innovative multi-assay hardware with the group’s vast global commercial and R&D infrastructure
05/2024	BRUKER	ELITECH GROUP	FRANCE	Life Sciences	The successful acquisition of ELITechGroup by Bruker Corporation marks a definitive tactical expansion of the group's microbiology and infection diagnostics portfolio. This transaction facilitates the integration of ELITech’s innovative sample-to-result molecular diagnostic systems with Bruker’s existing microbial identification capabilities
05/2024	GTCR	SURMODICS	UNITED STATES	Life Sciences	GTCR agreed to acquire Surmodics as a take-private acquisition, financed through committed equity from GTCR-affiliated funds and committed debt financing. The strategic rationale rests on Surmodics’ position as a specialized healthcare technology platform with recurring exposure to medical device coatings and in vitro diagnostics
04/2024	KÜHNE HOLDING	AENOVA GROUP	GERMANY	Life Sciences	Kühne Holding AG has entered into a definitive agreement to acquire a majority stake in Aenova Group from the international investment firm BC Partners. In a move to ensure continuity and strategic alignment, funds advised by BC Partners will reinvest alongside Kühne Holding to maintain a minority position in the company
03/2024	ADVANCED MEDICAL SOLUTIONS GROUP	PÉTERS SURGICAL	FRANCE	Life Sciences	The acquisition of Peters Surgical by Advanced Medical Solutions Group plc is a strategic move to expand AMS's portfolio of surgical products and strengthen its presence in the global wound closure and tissue repair market
01/2024	MERCK & CO.	HARPOON THERAPEUTICS	UNITED STATES	Life Sciences	Merck has entered into a definitive agreement to acquire 100% of the outstanding shares of Harpoon Therapeutics. Strategically, this acquisition allows Merck to further diversify its oncology pipeline by integrating Harpoon’s proprietary TriTAC and ProTriTAC T-cell engager platforms
12/2023	MARLE GROUP	NOWAK	FRANCE	Life Sciences	Marle Group has acquired Nowak from a consortium of private equity investors led by Siparex Midcap, alongside Bpifrance, Unexo, and the management team. This acquisition strengthens Marle's vertical integration by adding specialized casting capabilities

REFERENCES

Revenue range: 10M - 30M GBP

EBITDA range: 0M - 5M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EXSCIENTIA by RECURSION PHARMACEUTICALS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: recursion pharmaceuticals